Convergent Therapeutics has circled up $90 million to develop next-gen radiopharmaceuticals in oncology, with its lead clinical program targeting prostate cancer. The Cambridge, Massachusetts-based ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A small biotech, armed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback